Comparison of PD-L1 expression before and after neoadjuvant chemoradiation or chemotherapy in stage III non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Koenig, D. [1 ]
Prince, S. Savic [2 ]
Trachsel, B. [3 ]
Hayoz, S. [3 ]
Pless, M. [4 ]
机构：
[1] Univ Hosp Basel, Med Oncol Dept, Basel, Switzerland
[2] Univ Hosp Basel, Inst Pathol & Med Genet, Pathol Dept, Basel, Switzerland
[3] SAKK, Swiss Grp Clin Canc Res, Bern, Switzerland
[4] KSW Kantonsspital Winterthur, Med Oncol & Tumor Ctr, Winterthur, Switzerland
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.10.021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5P
引用
收藏
页码：S1376 / S1376
页数：1
相关论文
共 50 条
  • [21] PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC)
    Jiang, Liyan
    Su, Xinying
    Zhang, Tianwei
    Yin, Xiaolu
    Zhang, Meizhuo
    Fu, Haihua
    Han, Hulin
    Sun, Yun
    Dong, Lili
    Qian, Jialin
    Xu, Yanhua
    Fu, Xuan
    Gavine, Paul R.
    Zhou, Yanbin
    Tian, Kun
    Huang, Jiaqi
    Shen, Dong
    Jiang, Haiyi
    Yao, Yihong
    Han, Baohui
    Gu, Yi
    ONCOTARGET, 2017, 8 (16) : 26845 - 26857
  • [22] TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC)
    Cao, Xiaobo
    Zhao, Yang
    Wang, Jing
    Dai, Bingbing
    Gentile, Emanuela
    Lin, Jing
    Pu, Xingxiang
    Ji, Lin
    Wu, Shuhong
    Meraz, Ismail
    Majidi, Mourad
    Roth, Jack A.
    ONCOTARGET, 2017, 8 (64) : 107621 - 107629
  • [23] PD-L1 expression in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy.
    Mamesaya, Nobuaki
    Kenmotsu, Hirotsugu
    Miyawaki, Eriko
    Kotake, Mie
    Kawamura, Takahisa
    Kobayashi, Haruki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] Retrospective analysis between PD-L1 expression and prognosis for stage III non-small cell lung cancer patients
    Tokito, Takaaki
    Azuma, Koichi
    Ishii, Hidenobu
    Yamada, Kazuhiko
    Hoshino, Tomoaki
    ANNALS OF ONCOLOGY, 2015, 26 : 97 - 97
  • [25] PD-L1 expression, EGFR mutations (EGFRm) and KRAS mutations (KRASm) in stage III unresectable non-small cell lung cancer (NSCLC) patients
    Cronin-Fenton, Deirdre
    Dalvi, Tapashi
    Hedgeman, Elizabeth
    Norgaard, Mette
    Pedersen, Lars
    Hansen, Hanh
    Fryzek, Jon
    Walker, Jill
    Mellemgaard, Anders
    Rasmussen, Torben R.
    Shire, Norah
    Rigas, James
    Potter, Danielle
    Hamilton-Dutoit, Stephen
    Sorensen, Henrik T.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 384 - 385
  • [26] PD-RAD:A translational study investigating PD-L1 expression after radiotherapy for non-small cell lung cancer (NSCLC)
    Kordbacheh, T.
    Chan, C.
    Faivre-Finn, C.
    Franks, K.
    McDonald, F.
    Forster, M.
    Mendes, R.
    Quezade, S.
    Dovedi, S.
    Ralph, C.
    Popat, S.
    Harrington, K.
    Melcher, A.
    Popple, A.
    Illidge, T.
    LUNG CANCER, 2017, 103 : S78 - S79
  • [27] Chemoradiation for stage III non-small cell lung cancer
    Ramella, Sara
    Fiore, Michele
    Iurato, Aurelia
    Trodella, Luca E.
    Trodella, Lucio
    D'Angelillo, Rolando M.
    EUROPEAN JOURNAL OF ONCOLOGY, 2013, 18 (01): : 5 - 13
  • [28] Prognostic significance of PD-L1 in stage II/III non-small cell lung cancer.
    Tural, Deniz
    Karaca, Mustafa
    Akar, Emre
    Okay, Damla
    Cil, Ibrahim
    Akyurek, Nalan
    Uner, Aytug
    Ozet, Ahmet
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] Effects of Neoadjuvant Therapy on Programmed Cell Death Ligand 1 (PD-L1) Expression and Immune Microenviroment in Non-Small Cell Lung Cancer (NSCLC)
    Tomaszewski, Kristen
    Huynh, Tiffany
    Kem, Marina
    Mino-Kenudson, Mari
    MODERN PATHOLOGY, 2018, 31 : 753 - 754
  • [30] COST-EFFECTIVENESS OF DURVALUMAB AFTER CHEMORADIATION IN STAGE III NON-SMALL CELL LUNG CANCER (NSCLC)
    Criss, S. D.
    Mooradian, M. J.
    Lumish, M. A.
    Reynolds, K. L.
    Kong, C. Y.
    VALUE IN HEALTH, 2018, 21 : S12 - S12
12345